Drug Database
AD

adalimumab (Taibowei / TQZ2301 / Tabovi)

✓ Approved

Nanjing Shunxin Pharmaceutical · TNF · Monoclonal Antibodies

What is adalimumab?

adalimumab is a monoclonal antibodies developed by Nanjing Shunxin Pharmaceutical. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesTaibowei, TQZ2301, Tabovi
CompanyNanjing Shunxin Pharmaceutical
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetTNF
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Nanjing Shunxin Pharmaceutical

Mechanism of Action

Molecular Targets

adalimumab acts on 1 molecular target:

TNFtumor necrosis factor (TNFA, TNF-alpha)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

adalimumab is developed for 10 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Eye disordersUveitis✓ Approved

+5 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedOcular immunology and inflammation2026-08-25

Relentless Placoid Chorioretinitis in a Patient with Atopic Dermatitis Treated with Dupilumab.

Ruiz-Lozano Raul E RE, Kuhn Jessica E JE, Malka Jonathan J, Kleiner Gary I GI et al.

Dupilumab is an injectable human IgG4 monoclonal antibody targeting the IL-4 receptor indicated for moderate to severe atopic dermatitis (AD) refractory to standard topical treatments. We report an association of dupilumab with non-infectious posterior uveitis in a 10-year-old boy. Case report. A 10-year-old boy was referred for specialty eye examination due to bilateral blurry vision, redness, and light sensitivity unresponsive to topical ocular corticosteroids in the setting of using dupilumab for severe AD. There was iritis and vitreitis and numerous yellow-white moderate-sized retinochoroidal lesions in both eyes, with evidence of retinal vasculitis in one eye. Optical coherence tomography showed sublesional choroidal swelling with sub-retinal pigment epithelial deposits, full thickness retinal hyperreflectivity, and overlying vitreous cells. Fluorescein angiography revealed early blockage and late staining of lesions. Indocyanine green angiography showed hypofluorescent lesions throughout the course. An extensive immunological and infectious workup was negative. Dupilumab was stopped with some improvement noted. He was started on oral corticosteroids with additional improvement and rapidly transitioned to steroid-sparing therapy with mycophenolate, methotrexate and adalimumab. New retinal hemorrhages and inflammatory signs resolved after starting adalimumab. Visual acuity was maintained at 20/20. He was diagnosed with relentless placoid chorioretinopathy - possible associated with dupilumab use, which was permanently discontinued. Relentless placoid chorioretinopathy is a rare sight-threatening posterior uveitis that is ordinarily classified as undifferentiated but, in this case, could be an immunologic reaction to dupilumab. The immunopathogenic mechanism is presumably related to dupilumab-mediated Th2 IL-4/IL-13 dual blockade which polarizes Th17 (IL-23/IL-17) responses.

PMID 42639744
Read full article →
PubMedFrontiers in immunology2026-08-25

Decidua macrophages display a restrained inflammatory profile during chorioamnionitis.

Pithia Neema N, Musumarra Carmelo V CV, Protti Giulia G, Del Vecchio Giorgia G et al.

Decidual macrophages (DMs) are strategically located at the maternal-fetal interface to orchestrate innate host defense while balancing tolerance to the allogenic fetus. An important pregnancy complication is chorioamnionitis characterized by infection/inflammation in the fetal membranes and the amniotic fluid with upregulation of TNFα and other pro-inflammatory cytokines. The goal of this study was to determine maternal vs fetal origin of DMs and to investigate whether TNF signaling play a role in DM response to chorioamnionitis. Decidua tissue from pregnant Rhesus macaques given intraamniotic injection of lipopolysaccharide/saline with or without the TNF inhibitor Adalimumab (n=33) and human subjects with/out chorioamnionitis (n=11) were used for bulk RNAseq, scRNAseq, and flow cytometry experiments. In both human and Rhesus macaques, DMs coordinately upregulate both pro- and anti-inflammatory cytokines during chorioamnionitis. Although DMs did not express TNF during chorioamnionitis, inhibition of TNF signaling downregulated 50% of LPS induced genes. About 4% of the DMs were of male fetus origin. These fetal origin DMs selectively upregulated IL6 mRNA during chorioamnionitis, suggesting a potential role in fetal immune priming. We suggest that DMs orchestrate a carefully balanced host defense with a restrained pro-inflammatory profile during chorioamnionitis to potentially prevent adverse outcomes while protecting the mother-fetus dyad. Activation of fetal origin macrophages during chorioamnionitis may have implications for shaping neonatal immune responses.

PMID 42638776
Read full article →
PubMedBMC ophthalmology2026-08-25

Sympathetic ophthalmia complicating proliferative diabetic retinopathy: diagnostic and therapeutic challenges during pregnancy.

Alshabib Norah N, Alarfaj Motazz M, Albahlal Abdullah A, Alyousif Nora A NA

Sympathetic ophthalmia is a rare, bilateral granulomatous uveitis that typically follows penetrating ocular trauma or intraocular surgery. Its coexistence with proliferative diabetic retinopathy is uncommon and complicates diagnosis and treatment. A 27-year-old woman with poorly controlled type 1 diabetes developed sympathetic ophthalmia in the fellow eye ten weeks after repair of a penetrating ocular injury. The sympathizing eye showed keratic precipitates, vitritis, papillitis, and exudative retinal detachment superimposed on proliferative diabetic retinopathy. High-dose intravenous methylprednisolone was initiated, followed by an oral taper and early introduction of adalimumab to reduce the risk of corticosteroid-induced hyperglycemia. After inflammatory control, panretinal photocoagulation was augmented. Visual acuity improved from 20/100 to 20/25 with marked resolution of subretinal fluid and partial regression of neovascularization. The clinical course was further complicated by a second pregnancy. The patient developed recurrent vitreous hemorrhage and progressive tractional changes that required postpartum pars plana vitrectomy; the eye remained quiet with a flat retina and visual acuity of 20/40 at last follow-up. This case underscores the importance of recognizing sympathetic ophthalmia as a potential inflammatory trigger for worsening diabetic retinopathy. Severe intraocular inflammation may exacerbate retinal ischemia and neovascular activity, whereas controlling sympathetic ophthalmia systemically can facilitate regression of diabetic changes. Early recognition and prompt, pregnancy-appropriate immunomodulatory therapy are critical to preserve vision and stabilize both inflammatory and microvascular disease components.

PMID 42638100
Read full article →
PubMedMedicine2026-08-22

Efficacy and safety evaluation of adalimumab for psoriatic arthritis: A meta-analysis.

Cai Zhiyue Z, Yan Le L, Zhang Yue Y

This study aims to conduct a systematic evaluation of the efficacy and safety of adalimumab (ADA) in treating psoriatic arthritis (PsA), providing evidence-based reference data for clinical medicine. A systematic search was conducted in PubMed, Embase, Web of Science, the Cochrane Library, as well as Chinese databases, including China National Knowledge Infrastructure, WanFang Data, and VIP Chinese Scientific Journals Database, to identify relevant randomized controlled trials of ADA for PsA. The final search was updated on June 10, 2026. Data were analyzed using Stata 15.0. This meta-analysis involved 17 studies, including 1 phase II clinical trial and 11 phase III clinical trials, covering 5655 patients. According to the meta-analysis, ADA demonstrated significant improvements in ACR20 (risk ratio [RR]: 2.27, 95% confidence interval [CI]: 1.83-2.83), ACR50 (RR: 3.92, 95% CI: 2.98-5.15), and ACR70 (RR: 5.75, 95% CI: 4.47-7.39) among PsA patients compared with the control group. In addition, it also improved PASI75 (RR: 7.07, 95% CI: 4.36-11.46), PASI90 (RR: 4.27, 95% CI: 1.64-11.14), and PASI100 (RR: 8.23, 95% CI: 3.89-17.40). Furthermore, ADA was associated with improvements in other relevant indicators, including PsA response criteria (RR: 2.45, 95% CI: 2.01-2.99), complete resolution of enthesitis (RR: 1.46, 95% CI: 1.22-1.74), and minimal disease activity (RR: 3.10, 95% CI: 2.58-3.73). The study also performed subgroup analyses for outcomes at different stages and dosing intervals. The results showed that there was no significant increase in the overall risk of adverse events (AEs; RR = 1.04) or serious AEs (RR = 1.13), and there was no notable increase in discontinuations due to AEs (RR = 1.46). In the context of specific AEs, ADA was associated with 11 types of AEs but showed almost no impact on the other 6 AEs. ADA demonstrated beneficial efficacy in treating PsA, as evidenced by improvements in relevant indicators. Meanwhile, ADA demonstrated overall clinical efficacy; however, it was associated with a significantly increased risk of elevated liver enzymes (alanine aminotransferase and aspartate aminotransferase), suggesting a potential signal of hepatotoxicity. While no increase in overall or serious AEs was observed, liver function monitoring may be warranted during treatment.

PMID 42629706
Read full article →
PubMedHand surgery & rehabilitation2026-08-22

Disease-Modifying Antirheumatic Drugs for Hand Osteoarthritis: A Systematic Review and Network Meta-analysis.

Dong Pei P, Zhao Qianle Q, Yang Bo B, Kang Wulin W et al.

To compare the symptomatic efficacy, safety, and exploratory structural evidence of disease-modifying antirheumatic drug therapies in patients with hand osteoarthritis, with particular attention to inflammatory and erosive phenotypes. We searched PubMed, Web of Science, Embase, the Cochrane Library, ClinicalTrials.gov, and the Chinese Clinical Trial Registry from inception to 12 March 2026 for randomized controlled trials evaluating disease-modifying antirheumatic drug therapies in hand osteoarthritis. Eligible trials included patients with general, inflammatory, erosive, or thumb-base hand osteoarthritis, while studies involving rheumatoid arthritis or other inflammatory arthritides were excluded. Interventions were classified as conventional synthetic or biologic disease-modifying antirheumatic drugs. Pain intensity and hand function were considered primary clinical outcomes. Inflammatory symptom-related outcomes, including swollen and painful joint counts and stiffness, were analysed separately. Treatment-emergent adverse events and serious adverse events were primary safety outcomes, while imaging and biomarker outcomes were treated as exploratory evidence related to potential structural disease modification. A frequentist network meta-analysis was performed. Continuous outcomes were summarized as standardized mean differences and dichotomous outcomes as odds ratios, both with 95% confidence intervals. Twelve randomized controlled trials involving 1317 participants and seven active disease-modifying antirheumatic drug therapies were included. Methotrexate and hydroxychloroquine were classified as conventional synthetic disease-modifying antirheumatic drugs, whereas adalimumab, etanercept, tocilizumab, lutikizumab, and otilimab were classified as biologic disease-modifying antirheumatic drugs. No eligible trial of a targeted synthetic disease-modifying antirheumatic drug was identified. For pain intensity outcomes, etanercept and tocilizumab were associated with lower long-term visual analogue scale pain than placebo, whereas no intervention showed consistent improvement in hand function. For inflammatory symptom-related outcomes, tocilizumab showed a short-term reduction in painful and swollen joint counts, and adalimumab reduced swollen joint counts in some analyses. However, these findings were outcome-specific, time-dependent, and largely based on sparse, placebo-centred networks. No clear differences were detected in overall treatment-emergent adverse events or serious adverse events, but safety evidence was limited by small sample sizes, short exposure durations, and inconsistent adverse-event reporting. Imaging and biomarker outcomes were heterogeneous and insufficient for quantitative synthesis across most endpoints. Current randomized evidence does not support the routine use of disease-modifying antirheumatic drugs for hand osteoarthritis. Selected biologic agents showed limited symptomatic signals, particularly in pain or inflammatory joint outcomes, but these findings should not be interpreted as evidence of disease modification. Structural and biomarker evidence remains exploratory and insufficient. Future trials should focus on phenotype-enriched hand osteoarthritis populations and use standardized clinical, imaging, biomarker, and safety outcomes. Level I, therapeutic studies. PROSPERO CRD420261353132.

PMID 42632595
Read full article →
PubMedJournal of visualized experiments : JoVE2026-08-22

Takayasu Arteritis in a Child with Chronic Active Proctitis of Unspecified Etiology: A Case Report with Diagnostic Challenges and Literature Review.

Yao Meimei M, Liu Fei F, Gao Tianji T, Zhao Min M et al.

Takayasu arteritis (TAK) is a rare large-vessel vasculitis in children. A 14-year-old girl presented with intermittent fever, elevated inflammatory markers (C-reactive protein up to 117.63 mg/L and erythrocyte sedimentation rate of 93 mm/h), and computed tomography angiography demonstrating diffuse wall thickening of the aortic arch and its major branches. She had a previous diagnosis of ulcerative colitis; however, colonoscopy and biopsy revealed severe chronic active proctitis with glandular architectural irregularity and occasional cryptitis, but without crypt abscesses or granulomas, and the overall findings were insufficient to confirm ulcerative colitis or intestinal Behçet's disease. Behçet's disease was excluded because of the absence of oral or genital ulcers, ocular lesions, and skin manifestations. The patient met both the 2010 EULAR/PReS/PRINTO and 2022 ACR/EULAR classification criteria for TAK. Initial treatment with prednisone and adalimumab induced remission. A disease flare in June 2025 (C-reactive protein, 53.43 mg/L; erythrocyte sedimentation rate, 50 mm/h; and worsening carotid artery wall thickening) was controlled by increasing the prednisone dose and adding tocilizumab. At the 10-month follow-up, she remained asymptomatic, with stable vascular findings. This case highlights the importance of applying rigorous diagnostic criteria to avoid overdiagnosis of Behçet's disease in children with TAK and nonspecific intestinal inflammation.

PMID 42631618
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about adalimumab